Tenofovir maleate is a nucleotide reverse transcriptase inhibitor with potential applications in the research of HIV and chronic hepatitis B. It inhibits the replication of both R5-tropic HIV-1 (BaL) and X4-tropic HIV-1 (IIIB) in activated PBMCs, as well as multiple laboratory strains and patient-derived HIV-1 isolates. When combined with M48U1 in a 0.25% HEC formulation, it exhibits synergistic antiretroviral activity against R5-tropic HIV-1 BaL infection without toxicity to PBMCs. In vivo, Tenofovir Disoproxil Fumarate demonstrates dose-dependent protection against vaginal HIV challenge in BLT humanized mice and significantly reduces HIV transmission. It also induces a dose-dependent decline in serum viremia in woodchucks chronically infected with woodchuck hepatitis virus (WHV) and shows safety and efficacy in the woodchuck model of chronic HBV infection.